Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 130 entries
Sorted by: Best Match Show Resources per page
[No title available]

Epilepsy research

Flaus A, Mellerio C, Rodrigo S, Brulon V, Lebon V, Chassoux F.
PMID: 34847426
Epilepsy Res. 2021 Dec;178:106819. doi: 10.1016/j.eplepsyres.2021.106819. Epub 2021 Nov 20.

PURPOSE: Hybrid PET/MR is a promising tool in focal drug-resistant epilepsy, however the additional value for the detection of epileptogenic lesions and surgical decision-making remains to be established.METHODS: We retrospectively compared RESULTS: The location of epileptic focus was temporal...

Cite
Flaus A, Mellerio C, Rodrigo S, et al. . Epilepsy Res. 2021;178:106819doi: 10.1016/j.eplepsyres.2021.106819.
Flaus, A., Mellerio, C., Rodrigo, S., Brulon, V., Lebon, V., & Chassoux, F. (2021). . Epilepsy research, 178106819. https://doi.org/10.1016/j.eplepsyres.2021.106819
Flaus, Anthime, et al. "." Epilepsy research vol. 178 (2021): 106819. doi: https://doi.org/10.1016/j.eplepsyres.2021.106819
Flaus A, Mellerio C, Rodrigo S, Brulon V, Lebon V, Chassoux F. . Epilepsy Res. 2021 Dec;178:106819. doi: 10.1016/j.eplepsyres.2021.106819. Epub 2021 Nov 20. PMID: 34847426.
Copy Download .nbib Format: NLM
A framework for automated gene selection in genomic applications.

Genetics in medicine : official journal of the American College of Medical Genetics

Lazo de la Vega L, Yu W, Machini K, Austin-Tse CA, Hao L, Blout Zawatsky CL, Mason-Suares H, Green RC, Rehm HL, Lebo MS.
PMID: 34113001
Genet Med. 2021 Oct;23(10):1993-1997. doi: 10.1038/s41436-021-01213-x. Epub 2021 Jun 10.

PURPOSE: An efficient framework to identify disease-associated genes is needed to evaluate genomic data for both individuals with an unknown disease etiology and those undergoing genomic screening. Here, we propose a framework for gene selection used in genomic analyses,...

Cite
Lazo de la Vega L, Yu W, Machini K, et al. A framework for automated gene selection in genomic applications. Genet Med. 2021;23(10):1993-1997doi: 10.1038/s41436-021-01213-x.
Lazo de la Vega, L., Yu, W., Machini, K., Austin-Tse, C. A., Hao, L., Blout Zawatsky, C. L., Mason-Suares, H., Green, R. C., Rehm, H. L., & Lebo, M. S. (2021). A framework for automated gene selection in genomic applications. Genetics in medicine : official journal of the American College of Medical Genetics, 23(10), 1993-1997. https://doi.org/10.1038/s41436-021-01213-x
Lazo de la Vega, L, et al. "A framework for automated gene selection in genomic applications." Genetics in medicine : official journal of the American College of Medical Genetics vol. 23,10 (2021): 1993-1997. doi: https://doi.org/10.1038/s41436-021-01213-x
Lazo de la Vega L, Yu W, Machini K, Austin-Tse CA, Hao L, Blout Zawatsky CL, Mason-Suares H, Green RC, Rehm HL, Lebo MS. A framework for automated gene selection in genomic applications. Genet Med. 2021 Oct;23(10):1993-1997. doi: 10.1038/s41436-021-01213-x. Epub 2021 Jun 10. PMID: 34113001; PMCID: PMC8487927.
Copy Download .nbib Format: NLM
Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence.

Pharmaceuticals (Basel, Switzerland)

Villas-Boas GR, Lavorato SN, Paes MM, de Carvalho PMG, Rescia VC, Cunha MS, de Magalhães-Filho MF, Ponsoni LF, de Carvalho AAV, de Lacerda RB, da S Leite L, da S Tavares-Henriques M, Lopes LAF, Oliveira LGR, Silva-Filho SE, da Silveira APS, Cuman RKN, de S Silva-Comar FM, Comar JF, do A Brasileiro L, Dos Santos JN, de Freitas WR, Leão KV, da Silva JG, Klein RC, Klein MHF, da S Ramos BH, Fernandes CKC, de L Ribas DG, Oesterreich SA.
PMID: 33673205
Pharmaceuticals (Basel). 2021 Feb 12;14(2). doi: 10.3390/ph14020148.

Serotonin (5-HT) receptors are found throughout central and peripheral nervous systems, mainly in brain regions involved in the neurobiology of anxiety and depression. 5-HT receptors are currently promising targets for discovering new drugs for treating disorders ranging from migraine...

Cite
Villas-Boas GR, Lavorato SN, Paes MM, et al. Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence. Pharmaceuticals (Basel). 2021;14(2)doi: 10.3390/ph14020148.
Villas-Boas, G. R., Lavorato, S. N., Paes, M. M., de Carvalho, P. M. G., Rescia, V. C., Cunha, M. S., de Magalhães-Filho, M. F., Ponsoni, L. F., de Carvalho, A. A. V., de Lacerda, R. B., da S Leite, L., da S Tavares-Henriques, M., Lopes, L. A. F., Oliveira, L. G. R., Silva-Filho, S. E., da Silveira, A. P. S., Cuman, R. K. N., de S Silva-Comar, F. M., Comar, J. F., do A Brasileiro, L., Dos Santos, J. N., de Freitas, W. R., Leão, K. V., da Silva, J. G., Klein, R. C., Klein, M. H. F., da S Ramos, B. H., Fernandes, C. K. C., de L Ribas, D. G., & Oesterreich, S. A. (2021). Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence. Pharmaceuticals (Basel, Switzerland), 14(2), . https://doi.org/10.3390/ph14020148
Villas-Boas, Gustavo R, et al. "Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence." Pharmaceuticals (Basel, Switzerland) vol. 14,2 (2021). doi: https://doi.org/10.3390/ph14020148
Villas-Boas GR, Lavorato SN, Paes MM, de Carvalho PMG, Rescia VC, Cunha MS, de Magalhães-Filho MF, Ponsoni LF, de Carvalho AAV, de Lacerda RB, da S Leite L, da S Tavares-Henriques M, Lopes LAF, Oliveira LGR, Silva-Filho SE, da Silveira APS, Cuman RKN, de S Silva-Comar FM, Comar JF, do A Brasileiro L, Dos Santos JN, de Freitas WR, Leão KV, da Silva JG, Klein RC, Klein MHF, da S Ramos BH, Fernandes CKC, de L Ribas DG, Oesterreich SA. Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence. Pharmaceuticals (Basel). 2021 Feb 12;14(2). doi: 10.3390/ph14020148. PMID: 33673205; PMCID: PMC7918669.
Copy Download .nbib Format: NLM
Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Bertrand D, Lemée V, Laurent C, Lemoine M, Hanoy M, Le Roy F, Nezam D, Pruteanu D, Lebourg L, Grange S, Plantier JC, Boyer O, Guerrot D, Candon S.
PMID: 35007383
Am J Transplant. 2022 Jan 10; doi: 10.1111/ajt.16954. Epub 2022 Jan 10.

No abstract available.

Cite
Bertrand D, Lemée V, Laurent C, et al. Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Am J Transplant. 2022;doi: 10.1111/ajt.16954.
Bertrand, D., Lemée, V., Laurent, C., Lemoine, M., Hanoy, M., Le Roy, F., Nezam, D., Pruteanu, D., Lebourg, L., Grange, S., Plantier, J. C., Boyer, O., Guerrot, D., & Candon, S. (2022). Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, . https://doi.org/10.1111/ajt.16954
Bertrand, Dominique, et al. "Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. (2022). doi: https://doi.org/10.1111/ajt.16954
Bertrand D, Lemée V, Laurent C, Lemoine M, Hanoy M, Le Roy F, Nezam D, Pruteanu D, Lebourg L, Grange S, Plantier JC, Boyer O, Guerrot D, Candon S. Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Am J Transplant. 2022 Jan 10; doi: 10.1111/ajt.16954. Epub 2022 Jan 10. PMID: 35007383.
Copy Download .nbib Format: NLM
Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection.

Journal of clinical medicine

Riou M, Oulehri W, Momas C, Rouyer O, Lebourg F, Meyer A, Enache I, Pistea C, Charloux A, Marcot C, de Blay F, Collange O, Mertes M, Andrès E, Talha S, Geny B.
PMID: 33806800
J Clin Med. 2021 Mar 23;10(6). doi: 10.3390/jcm10061318.

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide, with more than two million deaths. Evidence indicates the critical role of the vascular endothelium in its pathophysiology but, like potential changes in functional vasodilation, the vascular effect of...

Cite
Riou M, Oulehri W, Momas C, et al. Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection. J Clin Med. 2021;10(6)doi: 10.3390/jcm10061318.
Riou, M., Oulehri, W., Momas, C., Rouyer, O., Lebourg, F., Meyer, A., Enache, I., Pistea, C., Charloux, A., Marcot, C., de Blay, F., Collange, O., Mertes, M., Andrès, E., Talha, S., & Geny, B. (2021). Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection. Journal of clinical medicine, 10(6), . https://doi.org/10.3390/jcm10061318
Riou, Marianne, et al. "Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection." Journal of clinical medicine vol. 10,6 (2021). doi: https://doi.org/10.3390/jcm10061318
Riou M, Oulehri W, Momas C, Rouyer O, Lebourg F, Meyer A, Enache I, Pistea C, Charloux A, Marcot C, de Blay F, Collange O, Mertes M, Andrès E, Talha S, Geny B. Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection. J Clin Med. 2021 Mar 23;10(6). doi: 10.3390/jcm10061318. PMID: 33806800; PMCID: PMC8004847.
Copy Download .nbib Format: NLM
Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach.

Pharmaceuticals (Basel, Switzerland)

Leão RP, Cruz JV, da Costa GV, Cruz JN, Ferreira EFB, Silva RC, de Lima LR, Borges RS, Dos Santos GB, Santos CBR.
PMID: 32858871
Pharmaceuticals (Basel). 2020 Aug 26;13(9). doi: 10.3390/ph13090209.

The cyclooxygenase-2 receptor is a therapeutic target for planning potential drugs with anti-inflammatory activity. The selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib was selected as a pivot molecule to perform virtual ligand-based screening from six commercial databases. We performed the search...

Cite
Leão RP, Cruz JV, da Costa GV, et al. Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach. Pharmaceuticals (Basel). 2020;13(9)doi: 10.3390/ph13090209.
Leão, R. P., Cruz, J. V., da Costa, G. V., Cruz, J. N., Ferreira, E. F. B., Silva, R. C., de Lima, L. R., Borges, R. S., Dos Santos, G. B., & Santos, C. B. R. (2020). Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach. Pharmaceuticals (Basel, Switzerland), 13(9), . https://doi.org/10.3390/ph13090209
Leão, Rozires P, et al. "Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach." Pharmaceuticals (Basel, Switzerland) vol. 13,9 (2020). doi: https://doi.org/10.3390/ph13090209
Leão RP, Cruz JV, da Costa GV, Cruz JN, Ferreira EFB, Silva RC, de Lima LR, Borges RS, Dos Santos GB, Santos CBR. Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach. Pharmaceuticals (Basel). 2020 Aug 26;13(9). doi: 10.3390/ph13090209. PMID: 32858871; PMCID: PMC7559105.
Copy Download .nbib Format: NLM
Fibronectin-matrix sandwich-like microenvironments to manipulate cell fate.

Biomaterials science

Ballester-Beltrán J, Moratal D, Lebourg M, Salmerón-Sánchez M.
PMID: 32481864
Biomater Sci. 2014 Mar 03;2(3):381-389. doi: 10.1039/c3bm60248f. Epub 2013 Nov 25.

Conventional 2D substrates fail to represent the natural environment of cells surrounded by the 3D extracellular matrix (ECM). We have proposed sandwich-like microenvironments as a versatile tool to study cell behaviour under quasi-3D conditions. This is a system that...

Cite
Ballester-Beltrán J, Moratal D, Lebourg M, et al. Fibronectin-matrix sandwich-like microenvironments to manipulate cell fate. Biomater Sci. 2013;2(3):381-389doi: 10.1039/c3bm60248f.
Ballester-Beltrán, J., Moratal, D., Lebourg, M., & Salmerón-Sánchez, M. (2014). Fibronectin-matrix sandwich-like microenvironments to manipulate cell fate. Biomaterials science, 2(3), 381-389. https://doi.org/10.1039/c3bm60248f
Ballester-Beltrán, J, et al. "Fibronectin-matrix sandwich-like microenvironments to manipulate cell fate." Biomaterials science vol. 2,3 (2014): 381-389. doi: https://doi.org/10.1039/c3bm60248f
Ballester-Beltrán J, Moratal D, Lebourg M, Salmerón-Sánchez M. Fibronectin-matrix sandwich-like microenvironments to manipulate cell fate. Biomater Sci. 2014 Mar 03;2(3):381-389. doi: 10.1039/c3bm60248f. Epub 2013 Nov 25. PMID: 32481864.
Copy Download .nbib Format: NLM
Catalytic conversion of methane to methanol on Cu-SSZ-13 using N.

Chemical communications (Cambridge, England)

Ipek B, Lobo RF.
PMID: 27790665
Chem Commun (Camb). 2016 Nov 08;52(91):13401-13404. doi: 10.1039/c6cc07893a.

Direct catalytic methanol production from methane is achieved on Cu-SSZ-13 zeolite catalysts using N

Cite
Ipek B, Lobo RF. Catalytic conversion of methane to methanol on Cu-SSZ-13 using N. Chem Commun (Camb). 2016;52(91):13401-13404doi: 10.1039/c6cc07893a.
Ipek, B., & Lobo, R. F. (2016). Catalytic conversion of methane to methanol on Cu-SSZ-13 using N. Chemical communications (Cambridge, England), 52(91), 13401-13404. https://doi.org/10.1039/c6cc07893a
Ipek, B, and Lobo, R F. "Catalytic conversion of methane to methanol on Cu-SSZ-13 using N." Chemical communications (Cambridge, England) vol. 52,91 (2016): 13401-13404. doi: https://doi.org/10.1039/c6cc07893a
Ipek B, Lobo RF. Catalytic conversion of methane to methanol on Cu-SSZ-13 using N. Chem Commun (Camb). 2016 Nov 08;52(91):13401-13404. doi: 10.1039/c6cc07893a. PMID: 27790665.
Copy Download .nbib Format: NLM
Genome Sequence of Airborne Acinetobacter sp. Strain 5-2Ac02 in the Hospital Environment, Close to the Species of Acinetobacter towneri.

Genome announcements

Barbosa BG, Fernandez-García L, Gato E, López M, Blasco L, Leão RS, Albano RM, Fernández B, Cuenca FF, Pascual Á, Bou G, Marques EA, Tomás M.
PMID: 27932646
Genome Announc. 2016 Dec 08;4(6). doi: 10.1128/genomeA.01343-16.

Acinetobacter spp. are found in 53% of air colonization samples from the hospital environment. In this work, we sequenced all the genome of airborne Acinetobacter sp. strain 5-2Ac02. We found important features at the genomic level in regards to...

Cite
Barbosa BG, Fernandez-García L, Gato E, et al. Genome Sequence of Airborne Acinetobacter sp. Strain 5-2Ac02 in the Hospital Environment, Close to the Species of Acinetobacter towneri. Genome Announc. 2016;4(6)doi: 10.1128/genomeA.01343-16.
Barbosa, B. G., Fernandez-García, L., Gato, E., López, M., Blasco, L., Leão, R. S., Albano, R. M., Fernández, B., Cuenca, F. F., Pascual, �. �., Bou, G., Marques, E. A., & Tomás, M. (2016). Genome Sequence of Airborne Acinetobacter sp. Strain 5-2Ac02 in the Hospital Environment, Close to the Species of Acinetobacter towneri. Genome announcements, 4(6), . https://doi.org/10.1128/genomeA.01343-16
Barbosa, Beathriz G V, et al. "Genome Sequence of Airborne Acinetobacter sp. Strain 5-2Ac02 in the Hospital Environment, Close to the Species of Acinetobacter towneri." Genome announcements vol. 4,6 (2016). doi: https://doi.org/10.1128/genomeA.01343-16
Barbosa BG, Fernandez-García L, Gato E, López M, Blasco L, Leão RS, Albano RM, Fernández B, Cuenca FF, Pascual Á, Bou G, Marques EA, Tomás M. Genome Sequence of Airborne Acinetobacter sp. Strain 5-2Ac02 in the Hospital Environment, Close to the Species of Acinetobacter towneri. Genome Announc. 2016 Dec 08;4(6). doi: 10.1128/genomeA.01343-16. PMID: 27932646; PMCID: PMC5146438.
Copy Download .nbib Format: NLM
The authors reply.

Critical care medicine

Ridgeon EE, Young PJ, Bellomo R, Mucchetti M, Lembo R, Landoni G.
PMID: 27755082
Crit Care Med. 2016 Nov;44(11):e1143. doi: 10.1097/CCM.0000000000002045.

No abstract available.

Cite
Ridgeon EE, Young PJ, Bellomo R, et al. The authors reply. Crit Care Med. 2016;44(11):e1143doi: 10.1097/CCM.0000000000002045.
Ridgeon, E. E., Young, P. J., Bellomo, R., Mucchetti, M., Lembo, R., & Landoni, G. (2016). The authors reply. Critical care medicine, 44(11), e1143. https://doi.org/10.1097/CCM.0000000000002045
Ridgeon, Elliott E, et al. "The authors reply." Critical care medicine vol. 44,11 (2016): e1143. doi: https://doi.org/10.1097/CCM.0000000000002045
Ridgeon EE, Young PJ, Bellomo R, Mucchetti M, Lembo R, Landoni G. The authors reply. Crit Care Med. 2016 Nov;44(11):e1143. doi: 10.1097/CCM.0000000000002045. PMID: 27755082.
Copy Download .nbib Format: NLM
SARS-CoV-2-specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19.

Transplantation direct

Bertrand D, Hamzaoui M, Drouot L, Lamulle J, Hanoy M, Edet S, Laurent C, Lebourg L, Etienne I, Lemoine M, Le Roy F, Nezam D, Mauger E, Boyer O, Guerrot D, Candon S.
PMID: 34805494
Transplant Direct. 2021 Nov 17;7(12):e792. doi: 10.1097/TXD.0000000000001230. eCollection 2021 Dec.

Kidney transplantation and dialysis are two major risk factors for severe forms of coronavirus disease 2019 (COVID-19). The dynamics of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this population remain largely unknown.METHODS: We report...

Cite
Bertrand D, Hamzaoui M, Drouot L, et al. SARS-CoV-2-specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19. Transplant Direct. 2021;7(12):e792doi: 10.1097/TXD.0000000000001230.
Bertrand, D., Hamzaoui, M., Drouot, L., Lamulle, J., Hanoy, M., Edet, S., Laurent, C., Lebourg, L., Etienne, I., Lemoine, M., Le Roy, F., Nezam, D., Mauger, E., Boyer, O., Guerrot, D., & Candon, S. (2021). SARS-CoV-2-specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19. Transplantation direct, 7(12), e792. https://doi.org/10.1097/TXD.0000000000001230
Bertrand, Dominique, et al. "SARS-CoV-2-specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19." Transplantation direct vol. 7,12 (2021): e792. doi: https://doi.org/10.1097/TXD.0000000000001230
Bertrand D, Hamzaoui M, Drouot L, Lamulle J, Hanoy M, Edet S, Laurent C, Lebourg L, Etienne I, Lemoine M, Le Roy F, Nezam D, Mauger E, Boyer O, Guerrot D, Candon S. SARS-CoV-2-specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19. Transplant Direct. 2021 Nov 17;7(12):e792. doi: 10.1097/TXD.0000000000001230. eCollection 2021 Dec. PMID: 34805494; PMCID: PMC8601300.
Copy Download .nbib Format: NLM
News about The Journal of the Society for Gynecologic Investigation.

Journal of the Society for Gynecologic Investigation

Lobo RA.
PMID: 11750864
J Soc Gynecol Investig. 2001 Nov-Dec;8(6):317.

No abstract available.

Cite
Lobo RA. News about The Journal of the Society for Gynecologic Investigation. J Soc Gynecol Investig. 2001;8(6):317
Lobo, R. A. (2001). News about The Journal of the Society for Gynecologic Investigation. Journal of the Society for Gynecologic Investigation, 8(6), 317.
Lobo, R A. "News about The Journal of the Society for Gynecologic Investigation." Journal of the Society for Gynecologic Investigation vol. 8,6 (2001): 317.
Lobo RA. News about The Journal of the Society for Gynecologic Investigation. J Soc Gynecol Investig. 2001 Nov-Dec;8(6):317. PMID: 11750864.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 130 entries